M&A Deal Summary |
|
|---|---|
| Date | 2019-02-25 |
| Target | Spark Therapeutics |
| Sector | Life Science |
| Buyer(s) | Roche |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.3B USD |
| Advisor(s) | Centerview Partners Cowen (Financial) Goodwin Procter (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1896 |
| Sector | Life Science |
| Employees | 100,920 |
| Revenue | 62.4B CHF (2024) |
Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It offers diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 34 of 44 |
| Sector: Life Science M&A | 22 of 31 |
| Type: Add-on Acquisition M&A Deals | 31 of 36 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 21 of 30 |
| Year: 2019 M&A | 1 of 3 |
| Size (of disclosed) | 5 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-09-28 |
Tusk Therapeutics
Hertfordshire, United Kingdom Tusk Therapeutics Ltd. is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune system to transform the treatment of cancer. The Company’s lead programme consists of a first-in-class antibody for the depletion of regulatory T-cells, based on the work of Dr. Sergio Quezada. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-06-19 |
Foundation Medicine
Cambridge, Massachusetts, United States Foundation Medicine, Inc. is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. |
Buy | $5.3B |
